Table 5.
Disease outcomes and medications used in juvenile myositis patients with and without anti-Ro52 autoantibodies
| Total (N=371) % (n/N) or Mean (SD) | Anti-Ro52 autoantibody positive (N=53) % (n/N) or Mean (SD) | Anti-Ro52 autoantibody negative (N=318) % (n/N) or Mean (SD) | Univariate p-value | Multivariate p-value | |
|---|---|---|---|---|---|
| Disease | |||||
| Monocyclic course | 22% (65/297) | 3% (1/37) b | 25% (64/260) c | 0.003 | 0.02 |
| Polycyclic course | 23% (68/297) | 19% (7/37) b | 23% (61/260) c | 0.5 | 0.9 |
| Chronic continuous course | 55% (164/297) | 78% (29/37) b | 52% (135/260) c | 0.002 | 0.05 |
| Steinbrocker functional class at final assessment | |||||
| Mean functional class | 1.4 (0.8) | 1.7 (1.0) | 1.4 (0.8) | 0.007 | 0.007 |
| Functional class 1 | 70% (257/367) | 53% (28/53) | 73% (229/314) c | 0.003 | 0.09 |
| Functional class 2 | 21% (77/367) | 34% (18/53) | 19% (59/314) c | 0.01 | 0.3 |
| Functional class 3 | 4% (13/367) | 2% (1/53) | 4% (12/314) c | 0.7 | 0.2 |
| Functional class 4 | 5% (20/367) | 11% (6/53) | 4% (14/314) c | 0.05 | 0.008 |
| Mortality | 4% (13/371) | 6% (3/53) | 3% (10/318) | 0.4 | 0.4 |
| Hospitalized | 58% (206/355) | 66% (35/53) | 57% (171/302) c | 0.2 | 0.4 |
| Mean number of hospitalizations | 1.3 (1.9) | 1.3 (1.4) | 1.3 (2.0) | 0.9 | 0.8 |
| Wheelchair use | 19% (68/360) | 24% (12/50) b | 18% (56/310) c | 0.3 | 0.2 |
| Response to treatment | |||||
| Complete clinical response | 30% (91/304) | 17% (7/42) | 32% (84/262) c | 0.04 | 0.4 |
| Remission | 24% (74/312) | 5% (2/43) | 27% (72/269) c | 0.002 | 0.05 |
| Total number of medications used | 3.9 (2.1) | 4.8 (2.5) | 3.8 (2.0) | 0.003 | 0.05 |
| Treatment trials per year | 2.3 (2.8) | 3.5 (3.0) | 2.2 (2.7) | 0.004 | 0.1 |
| Medications received | |||||
| Oral steroids | 99% (309/312) | 100% (43/43) b | 99% (266/269) c | 1.0 | . |
| Intravenous pulsed steroids | 56% (174/312) | 79% (34/43) b | 52% (140/269) c | < 0.001 | 0.03 |
| Methotrexate | 74% (230/312) | 86% (37/43) b | 72% (193/269) c | 0.05 | 0.4 |
| Intravenous immunoglobulin | 36% (112/312) | 49% (21/43) b | 34% (91/269) c | 0.06 | 0.08 |
| Other DMARDs | 23% (73/312) | 35% (15/43) b | 22% (58/269) c | 0.06 | 0.3 |
Dichotomous variables were represented as percentage (count/total), continuous variables as mean (SD). For the univariate analysis, dichotomous variables were compared using chi-squared or Fisheŕs exact tests, as appropriate while continuous variables were compared using Studentś t-test. Multivariate analysis used linear or logistic regression adjusted for length of follow-up, year of onset and autoantibodies.
Abbreviations: ACR: American College of Rheumatology, DMARDs: disease modifying anti-rheumatic agents
Azathioprine, Chlorambucil, Chloroquine, Colchicine, Cyclophosphamide, Cyclosporine, Dapsone, Hydroxychloroquine, Intravenous Immunoglobulin, Lefluonmide, Methotrexate, Mycophenolate mofetil, Sodium thiosulfate, Quinacrine
N ≠ 53 due to missing data
N ≠ 318 due to missing data